Ish Khanna, PhD - Co-founder and Chief Executive Officer
Dr. Khanna has over 30 years of pharmaceutical industry experience with proven record of success in advancing drug molecules from “concept to clinic and market” He has held Technical and Executive Leadership positions in pharmaceutical companies (Pfizer, Pharmacia, Searle, Dr. Reddy’s Labs, Kareus Therapeutics). Dr. Khanna is experienced in building balanced discovery portfolio comprising of First in Class, Best in Class and Drug Repositioning. Dr. Khanna’s areas of expertise include medicinal chemistry, PK/PD correlations of drug molecules, IP strategies, lead optimization strategies and novel therapeutics for pain, inflammation, cardiovascular and metabolic diseases. He is a co-inventor and co-author of over 100 patents and peer reviewed science publications. Dr. Khanna is co-inventor of celecoxib and multiple clinical agents across therapeutics.
Sivaram Pillarisetti, PhD - Co-founder
Dr. Pillarisetti has over 23 years of experience in research in Academia and Industry. Most recently he was head of research at Kareus Therapeutics and prior to that he was the Vice President of Research at Reddy US Therapeutics and Dr Reddy’s Laboratories (DRL). At DRL he headed the biology department and was managing activities from discovery to clinic. He has successfully brought several drug molecules from concept to clinic. Key accomplishments include three candidates in Phase 1/2 and several in preclinical development. He has been conducting research in the cardiovascular and metabolic diseases for over 18 years. Prior to Reddy US Therapeutics/Dr Reddy Laboratories, Dr. Pillarisetti had held faculty appointments at Columbia University and the North Shore-Long Island Jewish Health System in New York, where he established a peptide discovery program for Angion Biotech. His areas of expertise include Inflammation, Pain and Metabolic diseases. He is the author of over 50 research papers and review articles and inventor on several issued patents. Dr. Pillarisetti had been an investigator of the American Heart association (1996-99) and is a current member of the American Diabetes association and a fellow of the American Heart Association.
Robert Sarisky, PhD, MBA
Dr. Sarisky is a Business Development expert. Robert has over 25-years’ experience working in the pharmaceutical companies (Janssen, GSK, and FORMA Therapeutics) with track record of developing successful corporate strategies and business outcomes. Robert’s expertise encompasses - building innovative partnerships structures, budgeting and fiscal management, and developinglicensing and strategic collaborations. Robert has also gained broad therapeutic knowledge in inflammation and neurodegenerative diseases.
Nanna Finnerup, MD, PhD
Dr. Finnerup is a Professor in pain research at Danish Pain Research Center, Department of Clinical Medicine, Aarhus University. Her areas of interest include studying the pathophysiology and therapies for diabetic polyneuropathy, chemotherapy-induced neuropathic pain, and related neuropathic conditions. Prof Nanna has been involved in multiple clinical trials in neuropathic pain and have authored more than 150 publications in the field. Currently, Prof. Nanna is Chair of the Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) and a steering group member of the International Diabetic Neuropathy Center (IDNC).
David Hill, PhD
Dr. Hill has over 30 years of experience working in the pharmaceutical industry as a pharmacologist and a senior leader, starting and finishing his career with Merck. David’s areas of expertise include: drug-discovery for neuroscience, pain, and anesthesia, including the use of large and small animal experimental models, and utilization of the translational in-vivo and in-vitro technologies for a successful path from early discovery to the clinic. During last several years David has been involved in novel drug discovery programs to build strategies and objective measures to mitigate risk of clinical failure.
Bob Ings, PhD
Dr. Ings is a DMPK expert with 40 years experience including senior leadership positions (Roche, Daiichi, Amgen, Pharmacia, Servier). Dr. Ings contributed to multiple US and European successful registrations of new medicines whilst working in the Pharma industry. He has co-authered over 80 publications including several book chapters.
Richard Timmer, PhD
Dr. Timmer is an experienced business development/intellectual property professional and entrepreneur in the biopharmaceutical sector with more than 25 years in the chemical and life sciences industries ( Morris, Manning & Martin, LLP, Chemcore therapeutics, AIM Therapeutics and Dr Reddy Labs).